» » EMA Recommends Orphan-designated Medicine for the Treatment of Duchenne Muscular Dystrophy

EMA Recommends Orphan-designated Medicine for the Treatment of Duchenne Muscular Dystrophy

An orphan-designated medicine Translarna (ataluren), Recommended by The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) with granting a conditional marketing authorisation for the treatment of Duchenne muscular dystrophy caused by nonsense mutations. Translarna is to be used in patients aged five years and older who are able to walk. a href="http:http://ift.tt/1nsXwGz" target="_blank" class="vcontentshlink"Duchenne ...

Read More
You have just read an article categorized health titled EMA Recommends Orphan-designated Medicine for the Treatment of Duchenne Muscular Dystrophy.
Written by: editor - Monday, May 26, 2014

There are currently no comments for "EMA Recommends Orphan-designated Medicine for the Treatment of Duchenne Muscular Dystrophy"

Post a Comment

Subscribe to: Post Comments (Atom)